Amyloid imaging with PET in early Alzheimer disease diagnosis

Med Clin North Am. 2013 May;97(3):377-98. doi: 10.1016/j.mcna.2012.12.017.


In vivo imaging of amyloid-β (Aβ) with positron emission tomography has moved from the research arena into clinical practice. Clinicians working with cognitive decline and dementia must become familiar with its benefits and limitations. Amyloid imaging allows earlier diagnosis of Alzheimer disease and better differential diagnosis of dementia and provides prognostic information for mild cognitive impairment. It also has an increasingly important role in therapeutic trial recruitment and for evaluation of anti-Aβ treatments. Longitudinal observations are required to elucidate the role of Aβ deposition in the course of Alzheimer disease and provide information needed to fully use the prognostic power of this investigation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged
  • Alzheimer Disease / diagnostic imaging*
  • Alzheimer Disease / genetics
  • Alzheimer Disease / pathology
  • Amyloid beta-Peptides / analysis*
  • Amyloid beta-Peptides / genetics
  • Aniline Compounds
  • Asymptomatic Diseases*
  • Brain / diagnostic imaging*
  • Brain / pathology
  • Carbon Radioisotopes
  • Chromosome Aberrations
  • Cognitive Dysfunction / diagnostic imaging
  • Cognitive Dysfunction / genetics
  • Cognitive Dysfunction / pathology
  • DNA Mutational Analysis
  • Diagnosis, Differential
  • Disease Progression
  • Fluorine Radioisotopes
  • Genetic Carrier Screening
  • Humans
  • Positron-Emission Tomography*
  • Prognosis
  • Statistics as Topic
  • Thiazoles


  • 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole
  • Amyloid beta-Peptides
  • Aniline Compounds
  • Carbon Radioisotopes
  • Fluorine Radioisotopes
  • Thiazoles